The notices it replaced
- Reissues: PAR-18-530 Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional)
- 2 steps back: PAR-15-075 Academic-Industrial Partnerships for Translation of Technologies for Cancer Diagnosis and Treatment (R01)
Replaced by PAR-25-338.
Who won it before
111 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $64,328,274 in first-year total cost, median $594,720.
Most frequent study sections
- Special Emphasis Panel[ZRG1 SBIB-Q (57)]76
- Special Emphasis Panel[ZRG1 SBIB-D (57)]14
- Special Emphasis Panel[ZRG1 CTH-E (57)]12
- Special Emphasis Panel[ZRG1 SBIB-S (57)]3
- Special Emphasis Panel[ZRG1-SBIB-Q(57)R]3
Most frequent institutions
- MASSACHUSETTS GENERAL HOSPITAL7
- CASE WESTERN RESERVE UNIVERSITY4
- EMORY UNIVERSITY4
- JOHNS HOPKINS UNIVERSITY4
- STANFORD UNIVERSITY4
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2025 | Molecular subtyping of brain tumors using a blood-based multiplexed assay1R01CA291826-01A1 | BALAJ, LEONORACARTER, BOB S | MASSACHUSETTS GENERAL HOSPITAL, MA | $678,228 | ZRG1 |
| 2025 | Develop a novel therapy with immuno- and onco-targeting dual efficacies to treat the triple negative breast cancer1R01CA288387-01A1 | FANG, DEYULIU, HUIPING | NORTHWESTERN UNIVERSITY, IL | $661,072 | ZRG1 |
| 2025 | Lung Cancer Immunotherapy using new generation of TCR-engineered CD4 + T cells1R01CA302874-01 | WANG, RONGFU | UNIVERSITY OF SOUTHERN CALIFORNIA, CA | $650,450 | ZRG1 |
| 2025 | Developing purinergic receptor inverse agonists for treating triple negative breast cancer1R01CA293672-01A1 | JIANG, JEAN XRIQUELME, MANUELYUAN, YAXIA | UNIVERSITY OF TEXAS HLTH SCIENCE CENTER, TX | $616,071 | ZRG1 |
| 2024 | Clinical translation of a NexGen platform for quantifying protein networks in human biospecimens2R01CA235575-07 | PAULOVICH, AMANDA G | FRED HUTCHINSON CANCER CENTER, WA | $837,288 | ZRG1 |
| 2024 | Developing liquid biopsy tests for malignant effusions using artificial intelligence-assisted, morphology-based isolation of tumor cells1R01CA292019-01 | MAGBANUA, MARK JESUSMASAELI, MAHDOKHTROSENBLUTH, JENNIFER M. | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $679,188 | ZRG1 |
| 2024 | Enabling translation of cancer cell proliferation PET imaging via droplet radiochemistry technology1R01CA281901-01A1 | CHEN, KAIJONES, JASONVAN DAM, ROBERT MICHAEL | UNIVERSITY OF SOUTHERN CALIFORNIA, CA | $656,181 | ZRG1 |
| 2024 | Translating glycans into biomarkers1R01CA285370-01A1 | MEHTA, ANAND S. | MEDICAL UNIVERSITY OF SOUTH CAROLINA, SC | $596,254 | ZRG1 |
| 2024 | Real time scattered x-ray imaging for tumor motion tracking in radiotherapy.1R01CA285379-01A1 | JIA, XUNYANG, KAI | JOHNS HOPKINS UNIVERSITY, MD | $590,726 | ZRG1 |
| 2024 | A Real-Time Hyperspectral Laparoscopic Stereo Imaging System for Robot-Assisted Surgery1R01CA288379-01 | FEI, BAOWEI | UNIVERSITY OF TEXAS DALLAS, TX | $589,457 | ZRG1 |
| 2024 | Development of a Bioengineered Therapeutic Device for the Prevention of Lymphedema1R01CA285372-01A1 | HUANG, NGAN F.PAUKSHTO, MICHAEL VITOLDOVICH | PALO ALTO VETERANS INSTIT FOR RESEARCH, CA | $556,684 | ZRG1 |
| 2024 | A compact beam delivery system enabling ultra-fast dose delivery for upright proton therapy1R37CA288343-01 | NESTERUK, KONRAD PAWEL | MASSACHUSETTS GENERAL HOSPITAL, MA | $499,840 | ZRG1 |
| 2023 | Reflectance confocal microscopy-optical coherence tomography (RCM-OCT) imaging of oral lesions: Toward an affordable device and approach for developing countries1R01CA275789-01A1 | CHATURVEDI, PANKAJFOX, WILLIAM J.IFTIMIA, NICUSORRAJADHYAKSHA, MILIND | SLOAN-KETTERING INST CAN RESEARCH, NY | $728,739 | ZRG1 |
| 2023 | Therapeutic Targeting a Non-Hodgkin Lymphoma Driver Using AI1R01CA271546-01A1 | LI, YONG | BAYLOR COLLEGE OF MEDICINE, TX | $656,085 | ZRG1 |
| 2023 | EPR scanner for tumor oximetry in the clinic1R01CA269234-01A1 | KUPPUSAMY, PERIANNAN | DARTMOUTH COLLEGE, NH | $626,734 | ZRG1 |
| 2023 | 3-dimensional prompt gamma imaging for online proton beam dose verification1R01CA279013-01 | POLF, JERIMY C.REN, LEI | UNIVERSITY OF MARYLAND BALTIMORE, MD | $575,694 | ZRG1 |
| 2023 | Development of AI-Augmented quality assurance tools for radiation therapy1R01CA275772-01 | XING, LEI | STANFORD UNIVERSITY, CA | $550,091 | ZRG1 |
| 2023 | Ultra-High Performance Brain-dedicated PET scanner for Neurology and Neuro-oncology imaging1R01CA275942-01A1 | GONZALEZ MARTINEZ, ANTONIONEHMEH, SADEK | WEILL MEDICAL COLL OF CORNELL UNIV, NY | $542,685 | ZRG1 |
| 2022 | Portable, Low Field Brain Magnetic Resonance Imaging (MRI) for Acute Stroke1R01EB031114-01A1 · under PAR-18-530 | KIMBERLY, WILLIAM TAYLORROSEN, MATTHEW SCOTSHETH, KEVIN NAVIN | YALE UNIVERSITY, CT | $744,150 | ZRG1 |
| 2022 | A precision tumor neoantigen identification pipeline for cytotoxic T-lymphocyte-based cancer immunotherapies1R01CA265928-01 · under PAR-18-530 | REINHERZ, ELLIS L | DANA-FARBER CANCER INST, MA | $713,250 | ZRG1 |
| 2022 | Novel targeted therapy for treating Ovarian Cancer1R01CA266970-01A1 | NAIR, HAREESH BABUVADLAMUDI, RATNA K | UNIVERSITY OF TEXAS HLTH SCIENCE CENTER, TX | $689,000 | ZRG1 |
| 2022 | Validation of a novel 3D culture platform for TNBC treatment selection1R01CA271682-01A1 | GALLUP, DAVIDUENO, NAOTO T.YUN, KYUSON | METHODIST HOSPITAL RESEARCH INSTITUTE, TX | $644,226 | ZRG1 |
| 2022 | Academic Industrial Partnership on Advanced Perfusion MRI1R01EB031080-01A1 · under PAR-18-530 | CHANG, YULIN VDETRE, JOHN AWANG, ZE | UNIVERSITY OF PENNSYLVANIA, PA | $607,329 | ZRG1 |
| 2022 | Single Visit Clinical Validation of ScreenFire, a Low-Cost HPV Test: Efficacy and Cost Effectiveness (SCALE)1R01CA266059-01 · under PAR-18-530 | CREMER, MIRIAM | CLEVELAND CLINIC LERNER COM-CWRU, OH | $578,801 | ZRG1 |
| 2022 | WIRELESS MAGNETO-MECHANICAL CONTROL OF NEURAL ACTIVITY MEDIATED BY MAGNETIC NANODISCS1R56EB031848-01A1 | ROMERO URIBE, GABRIELA | UNIVERSITY OF TEXAS SAN ANTONIO, TX | $530,817 | ZRG1 |
| 2022 | Academic-Industrial Partnership to Develop Clinical Tools for Algorithmic Irreversible Electroporation of Inoperable Tumors1R01CA272550-01 | SANO, MICHAEL BENJAMIN | NORTH CAROLINA STATE UNIVERSITY RALEIGH, NC | $525,365 | ZRG1 |
| 2022 | Clinical Translation of Stimulated Raman Histology2R01CA226527-05 | ORRINGER, DANIEL | NEW YORK UNIVERSITY SCHOOL OF MEDICINE, NY | $492,852 | ZRG1 |
| 2022 | A Comprehensive Clinical fMRI Software Solution to Enable Mapping of Critical Functional Networks and Cerebrovascular Reactivity in the Brain1R01CA258788-01A1 · under PAR-18-530 | ELSINGER, CATHERINE LLIU, HO-LING ANTHONY | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $402,421 | ZRG1 |
| 2022 | Automated interactive definition of the clinical target volume in radiation oncology1R01CA266275-01 · under PAR-18-530 | BORTFELD, THOMAS R. | MASSACHUSETTS GENERAL HOSPITAL, MA | $329,887 | ZRG1 |
| 2022 | Markerless Motion Tracking of Lung Tumors using Dual Energy Imaging2R01CA207483-04A1 · under PAR-18-530 | LEHMANN, MATHIASROESKE, JOHN | LOYOLA UNIVERSITY CHICAGO, IL | $318,295 | ZRG1 |
| 2021 | The UroMonitor: Innovative Technology to Improve Management of Bladder Dysfunction1R56EB031042-01 · under PAR-18-530 | DAMASER, MARGOT S. | CLEVELAND CLINIC LERNER COM-CWRU, OH | $948,822 | ZRG1 |
| 2021 | Real-time spectroscopic photoacoustic/ultrasound (PAUS) scanner withsimultaneous fluence and motion compensation to guide and validateinterventions: system development and preclinical testing.1R01EB030484-01A1 · under PAR-18-530 | O'DONNELL, MATTHEW | UNIVERSITY OF WASHINGTON, WA | $747,636 | ZRG1 |
| 2021 | Multimodal Intraoral Imaging System for Oral Cancer Detection and Diagnosis in Low Resource Setting1R01DE030682-01 · under PAR-18-530 | LIANG, RONGGUANG | UNIVERSITY OF ARIZONA, AZ | $693,571 | ZRG1 |
| 2021 | Three-Dimensional Multi-Parametric Ultrasound for Monitoring Therapy of Liver Metastasis2R01CA195443-04 · under PAR-18-530 | EL KAFFAS, AHMED | STANFORD UNIVERSITY, CA | $693,277 | ZRG1 |
| 2021 | Lung Functional Avoidance Radiotherapy Using Hyperpolarized Xenon MRI1R01CA255434-01A1 · under PAR-18-530 | KADLECEK, STEPHEN JRUSET, IULIAN CONSTANTIN | XEMED, LLC, NH | $662,399 | ZRG1 |
| 2021 | Personalized Motion Management for Truly 4D Lung Radiotherapy1R01CA262017-01 · under PAR-18-530 | GULLAPALLI, RAO PSAWANT, AMIT | UNIVERSITY OF MARYLAND BALTIMORE, MD | $658,497 | ZRG1 |
| 2021 | Biopsy Tract Sealing Device with Magnetic Resonance and X-Ray Image Contrast1R01CA254964-01 · under PAR-18-530 | MAITLAND, DUNCAN J | TEXAS ENGINEERING EXPERIMENT STATION, TX | $639,391 | ZRG1 |
| 2021 | Fluorescence Lifetime Imaging/Spectroscopy System For Robotic Cancer Surgery Guidance2R01CA187427-07 · under PAR-18-530 | FARWELL, DONALD GREGORYMARCU, LAURASORGER, JONATHAN M. | UNIVERSITY OF CALIFORNIA AT DAVIS, CA | $633,669 | ZRG1 |
| 2021 | Human-like automated radiotherapy treatment planning via imitation learning1R01CA254377-01A1 · under PAR-18-530 | JIA, XUNJIANG, STEVE BINNGUYEN, DAN | UT SOUTHWESTERN MEDICAL CENTER, TX | $626,797 | ZRG1 |
| 2021 | Advancing molecular fluorescence-guided surgery platform2R01CA167413-06 · under PAR-18-530 | PAULSEN, KEITH D.SAMKOE, KIMBERLEY | DARTMOUTH COLLEGE, NH | $612,175 | ZRG1 |
| 2021 | Computer Aided Diagnostic System for Prostate Cancer Detection Using Quantitative Multiparametric MRI1R01CA241159-01A1 · under PAR-18-530 | METZGER, GREGORY JOHN | UNIVERSITY OF MINNESOTA, MN | $598,014 | ZRG1 |
| 2021 | Development of a Phenotype-based Predictive Analytic for Acute Myeloid Leukemia1R01CA262287-01 · under PAR-18-530 | MARK, TOMER MSAVONA, MICHAEL RWAGNER, JOSEPH P | VANDERBILT UNIVERSITY MEDICAL CENTER, TN | $597,007 | ZRG1 |
| 2021 | A transformative drug discovery platform for allosteric kinase inhibitors1R01CA255513-01 · under PAR-18-530 | LEVINSON, NICHOLAS MARKTHOMAS, DAVID D | UNIVERSITY OF MINNESOTA, MN | $596,314 | ZRG1 |
| 2021 | Development of an ultra-high dose rate rotational linac for FLASH Radiotherapy1R01CA255432-01 · under PAR-18-530 | BOUCHER, SALIMESHENG, KE | UNIVERSITY OF CALIFORNIA LOS ANGELES, CA | $594,720 | ZRG1 |
| 2021 | An ultra-high (FLASH) dose rate x-ray cabinet system for pre-clinical laboratory radiation research1R01CA262097-01 · under PAR-18-530 | REZAEE, MOHAMMAD | JOHNS HOPKINS UNIVERSITY, MD | $576,386 | ZRG1 |
| 2021 | Development of next generation 2HG and metabolic MR imaging for precision oncology of mutant IDH and wildtype glioma patients1R01CA255479-01 · under PAR-18-530 | ANDRONESI, OVIDIU C | MASSACHUSETTS GENERAL HOSPITAL, MA | $569,946 | ZRG1 |
| 2021 | Imaging Goggles for Fluorescence-Guided Surgery1R01EB030987-01A1 · under PAR-18-530 | ACHILEFU, SAMUELBURAS, WILLIAM ROBINSON | WASHINGTON UNIVERSITY, MO | $564,129 | ZRG1 |
| 2021 | Preclinical Electron Paramagnetic Resonance Tumor Imager1R01CA262159-01 · under PAR-18-530 | EATON, GARETH R | UNIVERSITY OF DENVER (COLORADO SEMINARY), CO | $539,291 | ZRG1 |
| 2020 | Molecular Photoacoustic Imaging for Diagnostics and Therapy Monitoring1R01EB028762-01 · under PAR-18-530 | BOUCHARD, RICHARD R. | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $649,539 | ZRG1 |
| 2020 | Depleting exosomes to improve responses to immune therapy in HNSCC1U01DE029759-01 · under PAR-18-530 | MARLEAU, ANNETTEWHITESIDE, THERESA L. | UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA | $627,000 | ZRG1 |
| 2020 | Low-cost mobile colposcopy and confocal imaging for global prevention of cervical cancer1R01CA251911-01 · under PAR-18-530 | RICHARDS-KORTUM, REBECCA R.SCHMELER, KATHLEEN | RICE UNIVERSITY, TX | $614,528 | ZRG1 |
| 2020 | In vivo dual-axis confocal microscopy of 5-ALA-induced PpIX to guide low-grade glioma resections1R01CA244170-01 · under PAR-18-530 | LIU, JONATHAN T.C.SANAI, NADER | UNIVERSITY OF WASHINGTON, WA | $607,334 | ZRG1 |
| 2020 | Novel IL-12 Gene Delivery Vehicles for Transformation of Solid Tumors1R01CA244872-01 · under PAR-18-530 | POLLACK, SETH M | FRED HUTCHINSON CANCER RESEARCH CENTER, WA | $584,926 | ZRG1 |
| 2020 | Point-of-care cellular and molecular pathology of breast tumors on a cell phone1R01CA248491-01 · under PAR-18-530 | CHILKOTI, ASHUTOSHHWANG, E.SHELLEY | DUKE UNIVERSITY, NC | $581,490 | ZRG1 |
| 2020 | In situ PEDSy and light delivery platform for Intracavitory Photodynamic Therapy1R01EB028778-01A1 · under PAR-18-530 | POTASEK, MARYZHU, TIMOTHY C. | UNIVERSITY OF PENNSYLVANIA, PA | $576,523 | ZRG1 |
| 2020 | Changing brachytherapy with MRI remnant-tumor segmentation and active-catheter placement1R01CA237005-01A1 · under PAR-18-530 | VISWANATHAN, AKILA | JOHNS HOPKINS UNIVERSITY, MD | $556,695 | ZRG1 |
| 2020 | Achieving Optimal Motor Function in Stroke Survivors via a Human-Centered Approach to Design an mHealth Platform1R01EB027777-01A1 · under PAR-18-530 | LEE, SUNGHOON | UNIVERSITY OF MASSACHUSETTS AMHERST, MA | $537,650 | ZRG1 |
| 2020 | Development of a multi-omic clinical decision platform to guide personalized therapy1R01CA244899-01A1 · under PAR-18-530 | PAREKH, SAMIR | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NY | $519,735 | ZRG1 |
| 2020 | Robot-Assisted 3D ICE Catheter for Cardiac Ablation1R01EB028278-01A1 · under PAR-18-530 | JAGADEESAN, JAYENDER | BRIGHAM AND WOMEN'S HOSPITAL, MA | $437,331 | ZRG1 |
| 2020 | Boron Nitride Nanosheets to Enhance Dental Composite Performance1R56DE029457-01 · under PAR-18-530 | WHANG, KYUMIN | UNIVERSITY OF TEXAS HLTH SCIENCE CENTER, TX | $427,105 | ZRG1 |
| 2020 | Detecting DICER1: A global partnership to cure pediatric lung cancer1R37CA244940-01 · under PAR-18-530 | SCHULTZ, KRIS ANN PINEKENSTEIN | CHILDREN'S HOSPITALS AND CLINICS, MN | $411,901 | ZRG1 |
| 2020 | Coronary Fractional Flow Reserve Determined Using MRI and CFD1R01EB027774-01A1 · under PAR-18-530 | OSHINSKI, JOHN N | EMORY UNIVERSITY, GA | $354,663 | ZRG1 |
| 2019 | Clinical translation of a NexGen platform for quantifying protein networks in human biospecimens1R01CA235575-01A1 · under PAR-18-530 | PAULOVICH, AMANDA G | FRED HUTCHINSON CANCER RESEARCH CENTER, WA | $737,466 | ZRG1 |
| 2019 | Lymph Node Quantification System for Multisite Clinical Trials1R01CA235589-01A1 · under PAR-18-530 | HARRIS, GORDON JKIKINIS, RON | BRIGHAM AND WOMEN'S HOSPITAL, MA | $683,973 | ZRG1 |
| 2019 | Dual function theranostic constructs for photoacoustic guided surgery and photodynamic therapy1R01CA231606-01A1 · under PAR-18-530 | HASAN, TAYYABA | MASSACHUSETTS GENERAL HOSPITAL, MA | $646,771 | ZRG1 |
| 2019 | Translation of a biomarker panel for the early detection of hepatocellular carcinoma1R01CA237659-01 · under PAR-18-530 | MARRERO, JORGE AMEHTA, ANAND S. | MEDICAL UNIVERSITY OF SOUTH CAROLINA, SC | $546,516 | ZRG1 |
| 2019 | Academic-Industry Partnership for the Translation of a 4D in vivo Dosimetry Approach for Radiation Therapy1R37CA240806-01A1 · under PAR-18-530 | CHEN, YONGXIANG, LIANGZHONG SHAWN | UNIVERSITY OF OKLAHOMA, OK | $452,783 | ZRG1 |
| 2019 | Anatomical Modeling to Improve the Precision of Image Guided Liver Ablation1R01CA235564-01A1 · under PAR-18-530 | BROCK, KRISTYODISIO, BRUNO C | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $362,435 | ZRG1 |
| 2018 | Multimodal MR-PET Machine Learning Approaches for Primary Prostate Cancer Characterization1R01CA218187-01A1 · under PAR-15-075 | CATANA, CIPRIAN | MASSACHUSETTS GENERAL HOSPITAL, MA | $684,119 | ZRG1 |
| 2018 | Quantitative Histomorphometric Risk Classifier (QuHbIC) in HPV + Oropharyngeal Carcinoma1R01CA220581-01A1 · under PAR-15-075 | LEWIS, JAMESMADABHUSHI, ANANT | CASE WESTERN RESERVE UNIVERSITY, OH | $671,111 | ZRG1 |
| 2018 | Computerized Histologic Risk Predictor (CHiRP) for Early Stage Lung Cancers1R01CA216579-01A1 · under PAR-15-075 | MADABHUSHI, ANANTVELCHETI, VAMSIDHAR | CASE WESTERN RESERVE UNIVERSITY, OH | $670,734 | ZRG1 |
| 2018 | Comparison of cervical intraepithelial neoplasia 2/3 treatment outcomes with a portable LMIC-adapted thermal ablation device vs. gas-based cryotherapy1R01CA218195-01A1 · under PAR-15-075 | CREMER, MIRIAM | CLEVELAND CLINIC LERNER COM-CWRU, OH | $669,209 | ZRG1 |
| 2018 | An Academic-Industry Partnership to Advance Functional Genomics for Personalized Oncology.1R01CA214428-01A1 · under PAR-15-075 | KEMP, CHRISTOPHER J | FRED HUTCHINSON CANCER RESEARCH CENTER, WA | $647,099 | ZRG1 |
| 2018 | Translating buccal nanocytology for lung cancer screening into clinical practice1R01CA225002-01A1 · under PAR-15-075 | BACKMAN, VADIMROY, HEMANT K.SUBRAMANIAN, HARIHARAN | NORTHWESTERN UNIVERSITY, IL | $638,469 | ZRG1 |
| 2018 | Molecular Digital CytoImaging for Leukemia Drug Screening1R01CA222095-01A1 · under PAR-15-075 | MARTIN, JODYVU, TOTHU Q | OREGON HEALTH & SCIENCE UNIVERSITY, OR | $605,517 | ZRG1 |
| 2018 | Clinical platform for high-throughput analyses of extracellular vesicles1R01CA229777-01 · under PAR-15-075 | LEE, HAKHOSKOG, JOHAN | MASSACHUSETTS GENERAL HOSPITAL, MA | $597,308 | ZRG1 |
| 2018 | Sharpening the edge in pencil-beam proton therapy: an aftermarket collimation system to better spare normal tissue during radiation treatment1R37CA226518-01A1 · under PAR-15-075 | HYER, DANIEL ELLIS | UNIVERSITY OF IOWA, IA | $589,726 | ZRG1 |
| 2018 | Academic-Industry Partnership for the Translation of a Novel Optical Imaging Approach to guide Endocrine Cancer Surgery1R01CA212147-01A1 · under PAR-15-075 | MAHADEVAN-JANSEN, ANITA | VANDERBILT UNIVERSITY, TN | $563,912 | ZRG1 |
| 2018 | Next generation small animal radiation research platform1R37CA214639-01A1 · under PAR-15-075 | JIA, XUN | UT SOUTHWESTERN MEDICAL CENTER, TX | $545,755 | ZRG1 |
| 2018 | Clinical Translation of Stimulated Raman Histology1R01CA226527-01 · under PAR-15-075 | ORRINGER, DANIEL | UNIVERSITY OF MICHIGAN AT ANN ARBOR, MI | $529,945 | ZRG1 |
| 2018 | Radioluminescence dosimetry solution for precision radiation therapy1R01CA223667-01A1 · under PAR-15-075 | XING, LEI | STANFORD UNIVERSITY, CA | $521,555 | ZRG1 |
| 2018 | Molecular complete response in blood as a predictor for pathologic complete response after neoadjuvant therapy for breast cancer1R01CA214494-01A1 · under PAR-15-075 | PARK, BEN HO | JOHNS HOPKINS UNIVERSITY, MD | $224,662 | ZRG1 |
| 2017 | CLINICAL TRANSLATION OF HYPERPOLARIZED 13C-UREA FOR CANCER MR MOLECULAR IMAGING1R01CA214554-01 · under PAR-15-075 | FERRONE, MARCUSHURD, RALPH EUGENEKURHANEWICZ, JOHN | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $684,591 | ZRG1 |
| 2017 | Large aperture and wideband modular ultrasound arrays for the diagnosis of liver cancer1R01CA211602-01A1 · under PAR-15-075 | FERRARA, KATHERINE WTRAHEY, GREGG E.ZHOU, QIFA | UNIVERSITY OF CALIFORNIA AT DAVIS, CA | $667,368 | ZRG1 |
| 2017 | A Novel Molecular Imaging Agent for Surgical Resection of Invasive Brain Tumors1R01CA217956-01 · under PAR-15-075 | BRADY-KALNAY, SUSANN MGASTINEAU, EDWARDSLOAN, ANDREW E | CASE WESTERN RESERVE UNIVERSITY, OH | $662,909 | ZRG1 |
| 2017 | Focal Laser Ablation of Prostate Cancer using MR/US Fusion1R01CA218547-01 · under PAR-15-075 | HU, JIMMARKS, LEONARD STEPHENNATARAJAN, SHYAMSONN, GEOFFREY | UNIVERSITY OF CALIFORNIA LOS ANGELES, CA | $627,518 | ZRG1 |
| 2017 | A blood test to identify prostate cancer patients at risk for visceral metastasis1R01CA218356-01 · under PAR-15-075 | POSADAS, EDWIN MELENCIOTSENG, HSIAN-RONG | CEDARS-SINAI MEDICAL CENTER, CA | $620,500 | ZRG1 |
| 2017 | Translation of a Clinical Molecular Diagnostic Assay for Bladder Cancer1R01CA206584-01A1 · under PAR-15-075 | GOODISON, STEVE | MAYO CLINIC JACKSONVILLE, FL | $618,256 | ZRG1 |
| 2017 | Development of a Four-Class, Molecular Subtyping Diagnostic for HPV-negative Head and Neck Cancer1R01CA211939-01A1 · under PAR-15-075 | HAYES, DAVID NZEVALLOS, JOSE P. | WASHINGTON UNIVERSITY, MO | $615,138 | ZRG1 |
| 2017 | A novel point of care test for oral and oropharyngeal cancer risk1R01CA204264-01A1 · under PAR-15-075 | CALIFANO, JOSEPH AFRANZMANN, ELIZABETH J | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $593,922 | ZRG1 |
| 2017 | Image guided targeted biopsy of clinically significant prostate cancer with acoustic radiation force2R01CA142824-06A1 · under PAR-15-075 | NIGHTINGALE, KATHRYN RADABAUGH | DUKE UNIVERSITY, NC | $546,174 | ZRG1 |
| 2017 | Clinical translation of 19F MRI to visualize cancer immunotherapeutic cells2R01CA134633-05 · under PAR-15-075 | AHRENS, ERIC T.COHEN, EZRA | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $540,493 | ZRG1 |
| 2017 | Targeted Molecular Imaging of Plectin-1; Bench to bedside and back again1R01CA216879-01 · under PAR-15-075 | KELLY, KIMBERLY A.SUTCLIFFE, JULIE L | UNIVERSITY OF CALIFORNIA AT DAVIS, CA | $524,668 | ZRG1 |
| 2017 | Automated Volumetric Molecular Ultrasound for Breast Cancer Imaging1R01CA218204-01 · under PAR-15-075 | DAHL, JEREMYDANIEL, BRUCE LDEMARTINI, WENDY | STANFORD UNIVERSITY, CA | $477,755 | ZRG1 |
| 2017 | 2D MR Correlational Spectroscopy Platform for Molecular and Genetic Characterizations of Glioma1R01CA203388-01A1 · under PAR-15-075 | MAO, HUIZHONG, XIAODONG | EMORY UNIVERSITY, GA | $427,689 | ZRG1 |
| 2017 | Markerless Motion Tracking of Lung Tumors Using Dual Energy Imaging1R01CA207483-01A1 · under PAR-15-075 | MOSTAFAVI, HASSANROESKE, JOHN | LOYOLA UNIVERSITY CHICAGO, IL | $385,045 | ZRG1 |
| 2017 | Improving the in vivo delivery and antitumor efficacy of antisense drugs1R01CA214550-01 · under PAR-15-075 | PANG, HONGBO | SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE, CA | $110,639 | ZRG1 |
| 2016 | Transforming the diagnosis and care of patients with CTCL using TCR sequencing1R01CA203721-01 · under PAR-15-075 | CLARK, RACHAEL ANNKUPPER, THOMAS S. | BRIGHAM AND WOMEN'S HOSPITAL, MA | $742,632 | ZRG1 |
| 2016 | Computerized histologic image predictor of cancer outcome1R01CA202752-01A1 · under PAR-15-075 | FELDMAN, MICHAEL DGANESAN, SHRIDARMADABHUSHI, ANANT | CASE WESTERN RESERVE UNIVERSITY, OH | $699,670 | ZRG1 |
| 2016 | Development of novel selective Rac inhibitors for refractory leukemias1R01CA202756-01A1 · under PAR-15-075 | WILLIAMS, DAVID A | BOSTON CHILDREN'S HOSPITAL, MA | $638,223 | ZRG1 |
| 2016 | Investigating Radiation-Induced Injury to Airways and Pulmonary Vasculature in Lung SABR1R01CA202761-01A1 · under PAR-15-075 | SAWANT, AMITTIMMERMAN, ROBERT D | UNIVERSITY OF MARYLAND BALTIMORE, MD | $608,909 | ZRG1 |
| 2016 | Integrated Tools for Quantitative Whole-Body Tumor Perfusion Imaging1R01CA202695-01A1 · under PAR-15-075 | GREEN, MARK AHUTCHINS, GARY D | INDIANA UNIVERSITY INDIANAPOLIS, IN | $591,408 | ZRG1 |
| 2016 | Pharmacogenomic and circulating tumor cell approach to individualized treatment of pancreatic cancer1R01CA202762-01A1 · under PAR-15-075 | RICIGLIANO, MARKYU, KENNETH H. | SLOAN-KETTERING INST CAN RESEARCH, NY | $575,993 | ZRG1 |
| 2016 | Biomarkers of Molecular Age to Predict the Toxicity of Cancer Chemotherapy1R01CA203023-01 · under PAR-15-075 | ELAM, AMANDAMITIN, NATALIAMUSS, HYMANSHARPLESS, NORMAN E | UNIV OF NORTH CAROLINA CHAPEL HILL, NC | $572,222 | ZRG1 |
| 2016 | Integrated Discovery Pipeline for Tumor Neoantigens1R01CA204261-01A1 · under PAR-15-075 | CARRENO, BEATRIZ M.LINETTE, GERALD P | UNIVERSITY OF PENNSYLVANIA, PA | $562,825 | ZRG1 |
| 2016 | Real-time monitoring of circulating pancreatic tumor cells and clusters1R01CA207643-01 · under PAR-15-075 | CARPENTER, ERICA | UNIVERSITY OF PENNSYLVANIA, PA | $544,582 | ZRG1 |
| 2016 | Membrane-based immunotherapy for triple negative breast cancer- a partnered approach1R01CA202763-01A1 · under PAR-15-075 | PACK, CHRISTOPHER DSELVARAJ, PERIASAMY | EMORY UNIVERSITY, GA | $502,655 | ZRG1 |
| 2016 | A partnership to enable clinical ctDNA testing for breast cancer recurrence1R01CA204253-01 · under PAR-15-075 | VARLEY, KATHERINE ELENA | UNIVERSITY OF UTAH, UT | $481,993 | ZRG1 |
| 2016 | Development of cell-free DNA assays for HCC screening and liquid biopsy1R01CA202769-01 · under PAR-15-075 | SU, YING-HSIU | BARUCH S. BLUMBERG INSTITUTE, PA | $432,900 | ZRG1 |
| 2016 | Targeted therapy of peritoneal carcinomatosis using theranostic nanoparticles1R01CA202846-01 · under PAR-15-075 | MAO, HUIWANG, YONGQIANG ANDREWYANG, LILY | EMORY UNIVERSITY, GA | $425,268 | ZRG1 |
| 2016 | Development of Anatomical Patient Models to Facilitate MR-only Treatment Planning1R01CA204189-01A1 · under PAR-15-075 | GLIDE-HURST, CARRI KAYE | HENRY FORD HEALTH SYSTEM, MI | $350,943 | ZRG1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.